Study S001886

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05929079
Acronym: TRIUMPH-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 1152
Start: 2023-07-11
Primary completion: 2026-06-16
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBK; OTHER:J1I-MC-GSA2; OTHER:2023-503658-11-00; NIH:2023

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, Week 80]
Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset [Baseline, Week 80]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010184	Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Bellido V, Lancet (London, England)	2026	Randomized trial	PMID 42810372 DOI	cites ClinicalTrials.gov:NCT05929079; registry reference DERIVED:42810372